Core Viewpoint - Huazhong Biopharmaceutical Company-B (02396) has successfully completed its IPO subscription, raising significant interest with an oversubscription rate of 594 times the public offering amount of HKD 90.02 million [1] Group 1: IPO Details - The IPO subscription period was from December 12 to December 17, with a total of HKD 53.6 billion in margin financing from brokers [1] - The company plans to issue 17.6488 million H-shares, with approximately 10% allocated for public offering and 90% for international offering, along with a 15% over-allotment option [1] - The share price is set between HKD 38.2 and HKD 51, with a minimum investment of HKD 10,302.9 for one lot of 200 shares, aiming to raise up to HKD 900 million [1] Group 2: Company Overview - Established in 2012, Huazhong Biopharmaceutical focuses on developing protein drugs for various therapeutic areas, particularly in wound healing therapies [1] - The company has two core products in its pipeline: Pro-101-1 for treating deep second-degree burns, which has completed IIb clinical trials, and Pro-101-2 for diabetic foot ulcers, currently in II phase clinical trials [2] Group 3: Market Position and Financials - As of the latest date, there are no approved PDGF products in the Chinese biopharmaceutical market, with Huazhong holding two of the three PDGF drug pipelines in the country [3] - The company has not yet commercialized any of its candidate products and has not generated any revenue from sales [3] - Financially, Huazhong reported net losses of RMB 105 million, RMB 212 million, and RMB 135 million for the fiscal years ending September 30 for 2023, 2024, and 2025, respectively, primarily due to R&D and administrative expenses [3] Group 4: Use of Proceeds - Approximately 61.8% of the net proceeds from the global offering will be allocated to the continued clinical development and commercialization of core products Pro-101-1 and Pro-101-2 [4] - About 18.8% will be used to enhance R&D capabilities through the purchase of specialized equipment and instruments [4] - The remaining proceeds will fund ongoing preclinical research for other PDGF products and operational expenses [4]
华芢\生物-B招股结束 孖展认购额达536亿港元 超购594倍